DOI: 10.55522/jhpo.V2I5.0047 Year 2025 - Volume 2 - Issue 5 ISSN NO: 3049 - 2637

Journal of Health Physiotherapy and Orthopaedics

Review Article

Mechanisms of bone resorption and skeletal protection in solid tumor metastases and use of denosumab as a potent drug

Somesh Kumar Saxena*, Chandradeep Prasad, Ankit Kumar Giri, Gulshan Beldar, Priyanshu Verma, Amit Verma

SAM College of Pharmacy, SAM Global University, Raisen, Madhya Pradesh, India

Corresponding author: Somesh Kumar Saxena ✉ somesh1207@gmail.com, **Orcid Id**: https://orcid.org/0000-0003-4824-2853

Received - 12-07-2025, **Revised** - 15-08-2024, **Accepted** - 20-09-2024 **(DD-MM-YYYY)**

Refer this article

Somesh Kumar Saxena, Chandradeep Prasad, Ankit Kumar Giri, Gulshan Beldar, Priyanshu Verma, Amit Verma, Mechanisms of bone resorption and skeletal protection in solid tumor metastases and use of denosumab as a potent drug, September-October 2025, V 2 - I 5, Pages - 18 – 27. Doi: https://doi.org/10.55522/jhpo.V2I5.0047.

ABSTRACT

Cancer that spreads to bones is actually a common and serious problem in patients with advanced tumors, especially from breast, prostate, and lung cancers. This bone spread definitely happens frequently and causes major complications. Tumor cells in bone tissue disturb normal bone repair process and further increase bone breakdown activity. This leads to bone problems like fractures, spinal cord pressure, and severe pain in the bone itself. The main cause of bone disease from tumors actually involves three key proteins - RANK, RANKL, and OPG - which definitely control how bone-breaking cells grow and work. As per research findings, too much RANKL protein at the tumor-bone area increases bone-eating cell activity, which causes bone damage and helps tumors grow. Regarding this process, the bone destruction and cancer spread happen together. Denosumab is a human antibody that blocks RANKL protein, which further stops bone breakdown cells from forming. This treatment itself targets the specific pathway that controls bone destruction. Basically, Denosumab works better than old bisphosphonates because you can inject it under the skin, it starts working fast, and it's the same safe option for patients with kidney problems. Also, clinical trials have further shown that the treatment itself reduces bone complications and improves life quality in patients with bone cancer spread from solid tumors. Basically, this review explains how cancer damages bones by focusing on the same RANK/RANKL/OPG pathway that controls bone breakdown. We are seeing studies that look at how stopping RANKL can help treat patients, what happens when doctors use Denosumab medicine, and what new bone treatments we can add to cancer care in future only.

Keywords: Bone metastases, RANKL inhibition, Denosumab, Skeletal-related events (SREs), Solid tumors, Osteoclast genesis, RANK/RANKL/OPG pathway.

INTRODUCTION

Bone metastases represent one of the most frequent and clinically challenging complications observed in patients with advanced solid tumors. Malignancies such as breast, prostate, and lung cancers exhibit a particularly high tendency for skeletal involvement, with research indicating that up to 70% of individuals with advanced-stage breast or prostate cancer and approximately 30–40% of those with lung cancer develop bone metastases during the progression of their disease. The formation of metastatic lesions within the bone is associated with a spectrum of debilitating skeletal-related events (SREs), including pathological fractures, spinal cord compression, hypercalcemia of malignancy, and persistent, severe bone pain [1]. These complications not only impair patients' physical function and independence but also contribute to a marked decline in survival rates and overall quality of life. The development of bone metastases involves

a highly intricate and dynamic interplay between tumor cells and the bone microenvironment, fundamentally disrupting the normal processes of bone remodeling. In healthy bone tissue, a delicate balance is maintained between osteoclastic bone resorption and osteoblastic bone formation to preserve skeletal integrity [2]. However, the presence of tumor cells within the bone alters this equilibrium, resulting in excessive osteoclast-mediated bone resorption. A central factor in this pathological process is the Receptor Activator of Nuclear Factor-kappa B (RANK) and its ligand (RANKL), a key signaling pathway that regulates osteoclast differentiation, activation, and survival. Under normal conditions, the activity of RANKL is controlled by osteoprotegerin (OPG), a decoy receptor that inhibits RANKL from binding to RANK, thereby preventing unchecked osteoclast genesis. In the setting of malignancy, both tumor cells and bone stromal cells within the metastatic environment upregulate RANKL expression, disrupting this regulatory mechanism and promoting osteoclastic bone destruction. In recent years, targeting the RANK/RANKL/OPG pathway has emerged as a significant therapeutic strategy in the management of cancer-induced bone disease. Denosumab, a fully human monoclonal antibody that specifically binds to and neutralizes RANKL, has demonstrated considerable efficacy in reducing the incidence of SREs and delaying skeletal complications in patients with bone metastases from solid tumors. Compared to conventional bisphosphonates, Denosumab offers several pharmacokinetic and clinical advantages, including faster onset of action, convenient subcutaneous administration, and suitability for patients with renal dysfunction, owing to its non-renal route of elimination. This review aims to provide a comprehensive analysis of the molecular mechanisms underlying bone resorption in solid tumor metastases, with particular emphasis on the RANK/RANKL/OPG signaling axis. Additionally, it evaluates the therapeutic potential of RANKL inhibition, summarizes clinical evidence supporting the use of Denosumab in oncology, and discusses emerging perspectives on incorporating bone-targeted therapies into multidisciplinary approaches to cancer care [3].

Literature review

Bone metastases are a common and clinically significant complication in patients with advanced solid tumors, particularly those originating from the breast, prostate, and lungs. Epidemiological data indicate that more than two-thirds of individuals with metastatic breast or prostate cancer, and approximately 30–40% of those with advanced lung cancer, eventually develop skeletal metastases during the course of their disease. These lesions are associated with an elevated risk of skeletal-related events (SREs), such as pathological fractures, spinal cord compression, hypercalcemia, and the need for palliative radiotherapy or orthopedic intervention. Managing these complications has become an essential aspect of supportive care in oncology, with bone-targeted therapies playing a key role in reducing their incidence and severity. The pathophysiology of bone metastases is driven by a destructive cycle of tumor-induced osteolysis. Within the bone microenvironment, tumor cells stimulate osteoclast formation and activity, resulting in excessive bone resorption. Central to this mechanism is the Receptor Activator of Nuclear Factor-kappa B Ligand (RANKL), a member of the tumor necrosis factor (TNF) superfamily. RANKL binds to its receptor, RANK, on the surface of osteoclast precursors and mature osteoclasts, promoting their differentiation, activation, and survival. Under normal physiological conditions, the activity of RANKL is regulated by osteoprotegerin (OPG), a soluble decoy receptor produced by osteoblasts and stromal cells, which prevents excessive osteoclast activation. In the presence of malignancy, however, tumor-derived factors and pro-inflammatory cytokines increase RANKL expression within the bone microenvironment, disrupting this balance and promoting osteoclastic bone resorption and tumor progression. Historically, bisphosphonates such as zoledronic acid and pamidronate have been the cornerstone of treatment for bone metastases. These agents inhibit osteoclast-mediated bone degradation by integrating into the bone matrix and inducing osteoclast apoptosis. While effective, their clinical use is sometimes limited by adverse effects, including potential renal toxicity and the risk of osteonecrosis of the jaw (ONJ) [4, 5].

Denosumab actually marked a major step forward in treating bone problems. This medicine definitely helped doctors target bone diseases much better. Basically, Denosumab is a human antibody that blocks RANKL from connecting to RANK, which stops the same cells that break down bones from forming and working. Many big studies have actually tested how safe and effective Denosumab is for patients who definitely have bone cancer spread from other

tumors. A major phase III trial compared Denosumab with zoledronic acid in breast cancer patients having bone metastases and found that Denosumab itself was better in delaying the first SRE and further reducing the risk of bone complications. Studies on prostate cancer and other solid tumors have surely shown similar results, and moreover, these findings establish Denosumab as a good alternative to bisphosphonates. Basically, Denosumab gives clinical benefits and also has pharmacokinetic advantages like subcutaneous injection and kidney-independent clearance, making it the same good option for patients with kidney problems. As per clinical studies, this medicine works fast and shows consistent results in the body, regarding its use in regular cancer treatment. Also, research studies surely show that blocking RANKL protein is very important for treating bone problems caused by cancer. Moreover, this treatment helps reduce patient symptoms and makes bone health better. [6].

Mechanism of bone resorption in solid tumor metastases

The skeletal system is a dynamic organ that continuously undergoes remodeling through a delicate balance between osteoclast-mediated bone resorption and osteoblast-driven bone formation. This tightly controlled process is essential for maintaining bone strength, mineral homeostasis, and structural integrity. Under normal physiological conditions, the coordinated actions of these two cell types preserve skeletal stability. However, the presence of metastatic tumor cells disrupts this balance, leading to excessive osteoclastic activity, pathological bone resorption, and progressive skeletal damage. Solid tumors such as breast, prostate, and lung cancers display a marked predilection for bone metastasis, largely attributed to the bone's rich vascular network and the abundance of growth factors sequestered within its matrix. Upon colonizing the bone microenvironment, tumor cells release a variety of cytokines, growth factors, and paracrine signaling molecules, including parathyroid hormone-related peptide (PTHrP), interleukins (IL-1, IL-6, IL-8, IL-11), tumor necrosis factor-alpha (TNF-α), and prostaglandin E2. These factors stimulate osteoblasts and bone marrow stromal cells to increase the expression of Receptor Activator of Nuclear Factor-kappa B Ligand (RANKL). RANKL is a crucial osteoclastogenic cytokine that binds to its receptor RANK, located on the surface of osteoclast precursors and mature osteoclasts. This interaction triggers a series of intracellular signaling pathways, including NF-κB, MAPK, and PI3K/Akt cascades, which promote osteoclast differentiation, activation, and extended survival. In healthy bone, osteoprotegerin (OPG)—a soluble decoy receptor produced by osteoblasts—binds to RANKL, preventing its interaction with RANK and thereby maintaining skeletal homeostasis by limiting osteoclast genesis. However, within the tumor-infiltrated bone microenvironment, excessive RANKL production combined with reduced OPG levels disturbs this regulatory balance. The resulting increase in osteoclast activity accelerates bone resorption, leading to the release of stored growth factors such as transforming growth factor-beta (TGF-β), insulin-like growth factors (IGFs), and platelet-derived growth factor (PDGF) from the bone matrix. These liberated factors further promote tumor cell proliferation, survival, and local invasion, thereby perpetuating a destructive cycle of bone degradation and tumor progression. This cycle of tumor-induced osteolysis not only leads to skeletal-related events (SREs), including pathological fractures, hypercalcemia, and spinal cord compression, but also creates a supportive niche for continued tumor growth, enhancing metastatic potential and adversely affecting patient survival. Given the pivotal role of the RANK/RANKL/OPG signaling axis in the development of bone metastases, therapeutic interventions targeting this pathway have gained considerable attention. Denosumab, a fully human monoclonal antibody that selectively binds to RANKL, effectively disrupts this vicious cycle by inhibiting osteoclast formation and activity. As a result, it preserves bone integrity and significantly reduces the risk of SREs in patients with solid tumors and skeletal metastases [7].

Denosumab: Mechanism of action and therapeutic role

Denosumab represents a significant advancement in the management of cancer-associated bone disease, particularly in patients with solid tumors that metastasize to the skeleton. It is a fully human monoclonal IgG2 antibody specifically engineered to target and neutralize Receptor Activator of Nuclear Factor-kappa B Ligand (RANKL), a critical regulator of osteoclast differentiation, activation, and survival. By blocking the interaction between RANKL and its receptor RANK on osteoclast precursors and mature osteoclasts, Denosumab effectively inhibits osteoclast formation and bone resorption, thereby reducing the incidence of skeletal-related events (SREs) and preserving bone integrity in patients with metastatic cancer. The therapeutic action of Denosumab is based on its high-affinity

binding to RANKL, preventing the activation of RANK receptors present on the surface of osteoclasts and their precursors. This inhibition disrupts essential downstream signaling pathways, including NF-κB, MAPK, and PI3K/Akt, which are involved in osteoclast genesis, cytoskeletal organization, and cell survival. As a result, Denosumab decreases both the number and activity of osteoclasts within the bone microenvironment. In contrast to bisphosphonates—which incorporate into bone tissue and indirectly induce osteoclast apoptosis by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway—Denosumab functions extracellularly, neutralizing RANKL before it can activate its receptor. This distinct mechanism provides several clinical advantages, including a rapid onset of action, predictable pharmacokinetics, and suitability for patients with renal impairment, as it is metabolized via the reticuloendothelial system rather than eliminated through the kidneys. Multiple clinical trials have confirmed the therapeutic benefits of Denosumab in managing bone metastases across a variety of solid tumors. A pivotal phase III study in patients with breast cancer metastatic to bone demonstrated that Denosumab significantly delayed the time to the first on-study SRE and reduced the risk of subsequent events when compared to zoledronic acid, the standard bisphosphonate therapy. Similar outcomes were reported in trials involving patients with metastatic prostate cancer and other solid malignancies, firmly establishing Denosumab as a superior alternative for preventing skeletal complications. Beyond its role in reducing SREs, Denosumab has also shown effectiveness in managing malignancy-associated hypercalcemia, particularly in patients unresponsive to bisphosphonates [8].

The convenience of subcutaneous administration further enhances patient compliance compared to the intravenous infusions required for bisphosphonates. However, while Denosumab offers considerable clinical advantages, it is not without risks. Reported adverse effects include hypocalcemia, osteonecrosis of the jaw (ONJ), and an increased risk of vertebral fractures following discontinuation of therapy. These potential complications necessitate vigilant patient monitoring and appropriate supplementation with calcium and vitamin D throughout treatment. In summary, Denosumab has emerged as a pivotal agent in the contemporary management of skeletal complications in patients with solid tumor bone metastases. Its novel mechanism of action, combined with favorable clinical outcomes and patient-friendly administration, has established it as an essential component of modern bone-targeted oncology care [10].

Figure 1: Molecular mechanism of bone resorption in solid tumour metastases



Figure 2: Protein structure of Denosumab



Clinical evidence and comparative studies

The therapeutic potential of Denosumab in managing bone metastases from solid tumors has been extensively investigated through numerous large-scale, multicenter, randomized controlled trials. These studies have consistently demonstrated its effectiveness in preventing skeletal-related events (SREs) and delaying disease progression, often with outcomes superior to those of traditional bisphosphonate therapy. One of the pivotal phase III trials assessing Denosumab's efficacy was conducted in patients with breast cancer and bone metastases. In this study, Denosumab was compared with zoledronic acid, a widely used bisphosphonate, in terms of its ability to delay the time to the first on-study SRE and reduce the risk of subsequent events. The findings revealed that Denosumab significantly extended the median time to the first SRE by 8.2 months compared to zoledronic acid. Additionally, it achieved a 23% relative reduction in the risk of developing SREs, thereby establishing its superiority over conventional bisphosphonate therapy in this patient population. Similar benefits were observed in a separate phase III trial involving men with castration-resistant prostate cancer and bone metastases [11].

In this study, Denosumab delayed the time to the first SRE by 3.6 months relative to zoledronic acid, with an 18% relative risk reduction. Denosumab's consistent efficacy has also been confirmed across other solid tumors, including lung cancer, renal cell carcinoma, and additional malignancies associated with skeletal involvement. A pooled analysis of several randomized trials further reinforced these results, demonstrating that Denosumab not only prevented SREs effectively but also improved bone metastasis-free survival in select tumor types. In addition to its clinical efficacy, Denosumab offers important pharmacological and practical advantages. Its subcutaneous route of administration improves patient convenience and compliance, while its non-renal metabolism makes it suitable for patients with compromised kidney function—a limitation often encountered with bisphosphonates, which require intravenous infusion and carry a risk of nephrotoxicity. Beyond its role in preventing skeletal complications, Denosumab has shown efficacy in managing malignancy-associated hypercalcemia, particularly in patients unresponsive to bisphosphonate therapy. Clinical studies have demonstrated its ability to normalize elevated serum calcium levels and maintain long-term control of hypercalcemia, providing an important therapeutic option in this difficult-to-treat condition [12].

Comparative safety analyses between Denosumab and bisphosphonates have highlighted important distinctions. While the incidence of osteonecrosis of the jaw (ONJ) appears comparable between the two drug classes, Denosumab has been associated with a higher risk of hypocalcemia, necessitating regular monitoring of calcium levels and supplementation throughout the course of

treatment. Moreover, emerging evidence has suggested a potential rebound phenomenon, characterized by an increased risk of vertebral fractures following abrupt discontinuation of Denosumab therapy. This concern underscores the importance of carefully planned treatment transitions to mitigate such risks.

In summary; extensive clinical evidence supports Denosumab's superiority over bisphosphonates in reducing skeletal complications in patients with solid tumor bone metastases. Its proven efficacy, ease of administration, and favorable safety profile have firmly positioned it as a first-line, bone-targeted therapeutic agent in contemporary oncology practice [13].

Pharmacokinetics and pharmacodynamics of denosumab

Denosumab possesses a distinctive pharmacokinetic and pharmacodynamic profile that sets it apart from other bone-modifying agents commonly used in oncology, particularly bisphosphonates. As a fully human monoclonal IgG2 antibody, Denosumab is administered via subcutaneous injection, typically at a dose of 120 mg every four weeks for patients with bone metastases from solid tumors. Its pharmacokinetics are nonlinear and dose-dependent, with an estimated bioavailability of approximately 61%, influenced by its protein-based nature and the subcutaneous route of delivery. Following administration, peak plasma concentrations are typically achieved within 10 days, after which the drug enters a prolonged elimination phase. The terminal half-life ranges between 25 to 28 days, allowing for extended dosing intervals and consistent suppression of bone resorption markers. Denosumab undergoes metabolism through the reticuloendothelial system via nonspecific proteolytic degradation into peptides and amino acids. Notably, this metabolic pathway is independent of renal function, making Denosumab an appropriate choice for patients with renal impairment, a population at increased risk of skeletal complications and often unsuitable for bisphosphonate therapy due to the potential for nephrotoxicity. Pharmaco dynamically, Denosumab acts by binding with high affinity to the Receptor Activator of Nuclear Factor-kappa B Ligand (RANKL), a pivotal cytokine produced by osteoblasts, stromal cells, and tumor cells within the bone microenvironment. By preventing RANKL from interacting with its receptor RANK on osteoclast precursors and mature osteoclasts, Denosumab effectively inhibits osteoclast differentiation, activation, and survival. This leads to a rapid and sustained reduction in bone resorption activity. The effect of Denosumab on bone turnover markers is both dose-dependent and reversible. Clinical data have shown that serum C-terminal telopeptide of type I collagen (CTX), a sensitive marker of bone resorption, is significantly suppressed within three days of administration, reaching maximum suppression within one month. Continued dosing maintains this effect; however, if treatment is interrupted or discontinued, bone turnover markers begin to rise, reflecting the reversible nature of Denosumab's action. This reversibility is clinically relevant, as abrupt cessation has been associated with rebound-associated vertebral fractures, particularly in osteoporosis and malignancy contexts, necessitating careful treatment transition strategies. Unlike bisphosphonates, which accumulate within the bone matrix and continue exerting antiresorptive effects long after discontinuation, Denosumab's effects diminish once it is cleared from systemic circulation. While this feature allows for more precise control over bone turnover when required, it also demands close clinical monitoring to prevent complications from rapid bone turnover recovery. In conclusion, Denosumab's favorable pharmacokinetic characteristics, consistent and reversible pharmacodynamic effects, and lack of dependence on renal excretion have firmly established it as a safe, effective, and convenient therapeutic option for the prevention and management of skeletal-related events in patients with solid tumor bone metastases [14].

Management of adverse effects associated with denosumab

Despite its clinical advantages, Denosumab therapy is associated with several adverse effects that necessitate careful monitoring and proactive management. The most frequent and clinically significant complication is hypocalcemia, resulting from the profound suppression of osteoclast-mediated bone resorption and reduced calcium mobilization from the skeletal stores. The risk of hypocalcemia is particularly heightened in patients with pre-existing vitamin D deficiency, extensive skeletal metastases, impaired renal function, or those receiving concurrent nephrotoxic medications. Reported incidences of hypocalcemia in cancer patients treated with Denosumab range from 8% to 14%, with severe cases occasionally requiring intravenous calcium supplementation. To minimize

this risk, it is recommended to correct vitamin D deficiency prior to initiating treatment, ensure adequate dietary calcium intake, and provide prophylactic supplementation of at least 500 mg of calcium and 400 IU of vitamin D daily throughout the course of therapy. Additionally, regular monitoring of serum calcium, phosphate, and magnesium levels is essential, particularly during the initial weeks of treatment. Another serious, though relatively uncommon, adverse event is osteonecrosis of the jaw (ONJ). This condition is characterized by exposed, non-healing bone in the maxillofacial region, often triggered by dental extractions or invasive oral procedures. The incidence of ONJ in patients receiving Denosumab for bone metastases is estimated at approximately 1% to 2%. Preventive strategies include conducting thorough dental evaluations before starting therapy, avoiding elective invasive dental interventions during treatment, and promptly managing any oral infections or trauma. A notable complication associated with Denosumab is the rebound phenomenon observed upon abrupt discontinuation. While predominantly recognized in osteoporosis management, this effect has also been increasingly reported in oncology.

The sudden resurgence of osteoclast activity leads to a sharp increase in bone turnover markers and significantly raises the risk of spontaneous, multiple vertebral fractures within months of stopping therapy. To counteract this risk, clinical guidelines recommend the sequential use of bisphosphonates following Denosumab discontinuation to stabilize bone remodeling and prevent rapid bone loss. Other reported adverse effects include musculoskeletal pain, fatigue, nausea, and an increased susceptibility to infections, particularly affecting the respiratory and urinary tracts. Hypersensitivity reactions and dermatologic events such as rashes and eczema, though rare, have also been documented. For safe and effective Denosumab use in oncology patients, a comprehensive adverse event monitoring strategy is essential. This should involve baseline risk assessments, routine biochemical evaluations, patient education on symptom recognition and reporting, and close coordination with dental and supportive care services.

Emerging RANKL inhibitors and alternative bone-targeted agents

While Denosumab has markedly improved the management of skeletal metastases in solid tumors, ongoing research continues to investigate novel RANKL inhibitors and alternative therapeutic strategies aimed at enhancing patient outcomes. Several investigational agents targeting the RANK/RANKL/osteoprotegerin (OPG) axis and other osteolytic signaling pathways are currently in various stages of preclinical and clinical development. Among these, osteoprotegerin-Fc (OPG-Fc) fusion proteins have emerged as a promising class of agents. These biologics function as decoy receptors, mimicking the activity of endogenous osteoprotegerin by binding to RANKL and preventing its interaction with the RANK receptor. Preclinical studies have demonstrated that OPG-Fc constructs possess improved binding affinity and extended duration of action compared to native osteoprotegerin, suggesting potential benefits in treating conditions associated with pathological bone resorption. Additionally, bispecific monoclonal antibodies designed to simultaneously target RANKL and other pro-osteolytic or tumor-promoting factors—such as interleukin-6 (IL-6) or Dickkopf-1 (DKK1)—are under active investigation. These agents aim to deliver dual therapeutic effects by modulating both the bone microenvironment and tumor progression pathways. Alternative anti-resorptive strategies include the development of cathepsin K inhibitors, such as odanacatib, which directly inhibit cathepsin K—a protease critical for the degradation of collagen in bone by osteoclasts [15].

Although odanacatib's clinical development was discontinued due to cardiovascular safety concerns, its mechanism of action has underscored a valuable therapeutic target, encouraging the exploration of safer agents within this class. Moreover, interest has grown in emerging anabolic therapies that stimulate bone formation. Agents targeting inhibitory proteins such as sclerostin (SOST) and DKK1 have shown potential by promoting osteoblastic activity, providing a complementary strategy alongside anti-resorptive treatments to preserve skeletal integrity in the context of tumor-induced bone loss. In parallel, combination treatment approaches integrating RANKL inhibitors with immune checkpoint inhibitors (ICIs), anti-angiogenic agents, or bone-targeted radiopharmaceuticals are being actively evaluated in clinical trials. These multimodal strategies aim to exploit the immunomodulatory and microenvironmental effects of bone-targeted therapy while enhancing systemic anti-tumor efficacy. Collectively, these innovative and combinational therapeutic avenues hold promise to broaden the future

landscape of bone-directed treatments, offering more personalized, effective, and safer options for patients suffering from metastatic bone disease [16].

Future perspectives

The management of bone metastases in solid tumors has progressed substantially with the introduction of targeted anti-resorptive agents like Denosumab. Despite its clinical success, several unmet challenges persist, necessitating continued research to refine therapeutic strategies, improve patient outcomes, and broaden the scope of skeletal protection in oncology. The future of bone-targeted therapy lies in deepening our understanding of the tumor–bone microenvironment, identifying predictive biomarkers, and developing next-generation agents capable of overcoming current limitations. A particularly promising area involves identifying molecular biomarkers that can predict patient response to RANKL inhibition and the risk of skeletal-related events (SREs). Biomarkers such as circulating RANKL, osteoprotegerin (OPG) levels, and bone turnover markers—including C-terminal telopeptide of type I collagen (CTX) and procollagen type I N-terminal propeptide (P1NP)—could enable patient stratification, allowing for more personalized, optimized anti-resorptive therapy in terms of intensity and duration. Additionally, integrating genetic polymorphisms within the RANK/RANKL/OPG signaling pathway into clinical decision-making algorithms could provide both predictive and prognostic value, further enhancing individualized treatment approaches. Another expanding area of interest is the investigation of combination therapies targeting multiple pathways implicated in the pathogenesis of bone metastases. Combining Denosumab with immune checkpoint inhibitors (ICIs) represents a particularly compelling strategy, supported by preclinical evidence suggesting that modulating bone resorption may favorably alter the immunosuppressive tumor microenvironment within bone and enhance anti-tumor immune responses. Parallel efforts are underway to develop next-generation RANKL inhibitors with improved pharmacokinetics, extended half-lives, and dual-targeting capabilities. Bispecific antibodies and fusion proteins designed to neutralize RANKL alongside other osteolytic or pro-tumorigenic mediators such as DKK1 or interleukin-6 (IL-6) hold significant potential for offering superior skeletal protection while attenuating metastatic tumor progression within bone. Moreover, anabolic bone agents targeting regulators of bone formation like sclerostin and DKK1 are being explored as adjunctive therapies to potent anti-resorptive agents. These agents may counteract the suppression of bone formation typically associated with long-term Denosumab therapy, helping to preserve bone mass and reduce fracture risk during extended treatment periods. Addressing the management of rebound-associated bone loss following Denosumab discontinuation remains another critical clinical priority. This phenomenon, marked by a rapid resurgence in bone turnover and heightened fracture risk, particularly vertebral fractures, presents a significant challenge in long-term management.

Although current evidence supports sequential bisphosphonate therapy post-Denosumab, the optimal timing, dosing, and choice of agent remain to be conclusively defined. Prospective studies are needed to establish standardized, evidence-based protocols to mitigate this risk while maintaining skeletal protection. Emerging bone-seeking radiopharmaceuticals, such as radium-223 and novel targeted alpha-therapies, represent another complementary therapeutic avenue. Their potential combination with RANKL inhibitors could synergistically reduce skeletal tumor burden and lower the incidence of SREs, though clinical data in this setting continue to evolve. Additionally, Denosumab's application beyond oncology—in conditions like rheumatoid arthritis, Paget's disease, and fibrous dysplasia—has expanded knowledge of its pharmacological effects and safety profile, providing insights that could inform its future use in cancer care. Finally, advancing real-world evidence studies and conducting thorough pharmacoeconomic analyses will be essential in assessing the long-term cost-effectiveness, safety, and patient-reported outcomes associated with Denosumab and other bone-targeted therapies. As healthcare systems increasingly prioritize value-based care models, demonstrating sustained clinical benefits with acceptable safety and economic profiles will be crucial in defining the future role of RANKL inhibitors within oncology treatment guidelines [17].

CONCLUSION

Bone metastases are a common and debilitating complication of advanced solid tumors, particularly those originating from breast, prostate, and lung cancers. These metastases significantly contribute to patient morbidity, reduced quality of life, and increased healthcare costs. The

underlying pathophysiology is closely associated with dysregulated osteoclast-mediated bone resorption, which is driven by tumor-derived factors and an imbalanced RANK/RANKL/osteoprotegerin signaling pathway. Targeting this pathway has become a key therapeutic strategy to prevent skeletal-related events (SREs), maintain bone integrity, and potentially limit tumor progression within the bone microenvironment. Among the available bone-modifying agents, Denosumab stands out due to its high efficacy and favorable safety profile. As a fully human monoclonal IgG2 antibody with specific targeting of RANKL, Denosumab offers advantages over traditional bisphosphonates, particularly with its subcutaneous administration, extended half-life, and independence from renal clearance. These features make Denosumab an ideal treatment option, particularly for patients with renal insufficiency who are not suitable candidates for bisphosphonates. Extensive clinical trials and real-world studies have demonstrated Denosumab's superiority or non-inferiority to bisphosphonates, such as zoledronic acid, in reducing and delaying SREs in patients with bone metastases from solid tumors. However, the use of Denosumab is not without its challenges. Adverse effects, including hypocalcemia, osteonecrosis of the jaw, and the potential for rebound-associated vertebral fractures upon discontinuation, underscore the importance of rigorous patient monitoring, early risk mitigation strategies, and personalized treatment planning. As oncology increasingly shifts toward precision medicine, there is a critical need for the identification of predictive biomarkers and clinical parameters that can guide patient selection and optimal treatment duration. Innovative therapeutic strategies are emerging that aim to further target the bone microenvironment. These include next-generation RANKL inhibitors, bispecific antibodies, anabolic agents, and combinations with immune-oncology therapies. These advances reflect a deeper understanding of the complex interactions between tumor cells, bone stromal cells, immune components, and osteoclast genesis mediators.

The integration of these novel agents with Denosumab holds promise for offering more comprehensive skeletal protection while simultaneously enhancing systemic disease control. Looking to the future, research must focus not only on expanding the therapeutic options available but also on refining clinical management protocols. This includes addressing long-term safety concerns with anti-resorptive therapies, determining optimal sequencing and combination strategies, and preventing skeletal fragility after discontinuation. Additionally, robust health economic evaluations and patient-centered outcomes research will be essential to establish the value proposition of Denosumab in metastatic cancer care. In conclusion; Denosumab has revolutionized the management of bone metastases in solid tumors by effectively disrupting the RANKL-mediated osteolytic pathway. Its clinical utility, coupled with ongoing advancements in our understanding of bone-tumor interactions and emerging therapeutic innovations, ushers in a new era of personalized, mechanism-based strategies for skeletal protection. These developments promise to improve both survival and quality of life for patients battling advanced malignancies.

REFERENCES

1. Wang M, Xia F, Wei Y, et al, 2020. Molecular mechanisms and clinical management of cancer bone metastasis. Bone Res. 8(30), Doi: https://doi.org/10.1038/s41413-020-00105-1.

2. Schmid-Alliana A, Schmid-Antomarchi, H Al-Sahlanee, et al, 2018. Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets. Int. J. Mol. Sci. 19, Pages 148. Doi: https://doi.org/10.3390/ijms19010148.

3. Henry DH, Costa L, Goldwasser F, et al, 1011. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer). J ClinOncol. 29(9), Pages 1125-1132. Doi: 10.1200/JCO.2010.31.3304.

4. Stopeck AT, Lipton A, Body JJ, et al, 2010. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28(35), Pages 5132-5139. Doi: 10.1200/JCO.2010.29.7101.

5. Fizazi K, Carducci M, Smith M, et al, 2011. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 377(9768), Pages 813-822. Doi: 10.1016/S0140-6736(10)62344-6.

6. Coleman RE, Croucher PI, Padhani AR, et al, 2020. Bone metastases. Nat Rev Dis Primers. 6(1), Pages 83. Doi: 10.1038/s41572-020-00216-3.

7. Boyce BF, Xing L, 2008. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch BiochemBiophys. 473(2), Pages 139-146. Doi: 10.1016/j.abb.2008.03.018.

8. Xie Z, Wang X, Wang X, et al, 2018. Denosumab: a potential new treatment for cancer-related bone metastasis. Cancer Manag Res. 10, Pages 789-799. Doi: 10.2147/CMAR.S156444.

9. Lipton A, 2013. Denosumab in breast cancer. CurrOncol Rep. 15(1), Pages 66-76. Doi: 10.1007/s11912-012-0273-6.

10. Tebben PJ, Khosla S, 2015. Antiresorptive therapies for osteoporosis and bone metastases. Mayo Clin Proc. 90(9), Pages 1230-1246. Doi: 10.1016/j.mayocp.2015.06.004.

11. Cummings SR, Ferrari S, Eastell R, et al, 2018. Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res. 33(2), Pages 190-198. Doi: 10.1002/jbmr.3337.

12. Barlev A, Joshi AV, Bansal M, et al, 2020. Osteonecrosis of the jaw in cancer patients with bone metastases treated with bisphosphonates or denosumab: a retrospective cohort study. J Bone Oncol. 22, Pages 100280. Doi: 10.1016/j.jbo.2020.100280.

13. Raje N, Terpos E, Willenbacher W, et al, 2018. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, randomized, double-blind, phase 3 study. Lancet Oncol. 19(3), Pages 370-381. Doi: 10.1016/S1470-2045(18)30072-X.

14. Vand V, Hoseini M, Heidari F, et al, 2019. Role of RANK/RANKL/OPG signaling in bone metastasis of breast cancer. J Cell Biochem. 120(4), Pages 5320-5330. Doi: 10.1002/jcb.27635.

15. Rucci N, Teti A, 2016. Bone metastases: pathophysiology and therapeutic implications. Clin Rev Bone Miner Metab. 14(3), Pages 111-126. Doi: 10.1007/s12018-016-9216-1.

16. Baron R, Ferrari S, Russell RG, 2011. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48(4), Pages 677-692. Doi: 10.1016/j.bone.2010.11.020.

17. Simões RL, 2017. Osteoprotegerin (OPG)/RANK/RANKL signaling pathway in bone pathophysiology. Rev Bras Reumatol Engl Ed. 57(3), Pages 299-309. Doi: 10.1016/j.rbre.2017.01.005